Finance

Lists
Why is CGON up 6.06%?
Dive Deeper
CGON:NASDAQ
CG Oncology Inc
$74.40
+6.06%
(+4.25) 1D
$74.40
0.00% (0.00)
After hours
Closed: Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CGON...
Open
$71.19
High
$76.06
Low
$68.13
Mkt. cap
6.65B
Avg. vol.
1.04M
Volume
3.31M
52-wk high
$80.97
52-wk low
$37.01
EPS
-$2.76
Shares outstanding
89.32M
No. of employees
142
Open
$71.19
High
$76.06
Low
$68.13
Mkt. cap
6.65B
Avg. vol.
1.04M
Volume
3.31M
52-wk high
$80.97
52-wk low
$37.01
EPS
-$2.76
Shares outstanding
89.32M
No. of employees
142
News stories
From web sources and news partners
About CG Oncology Inc
CEO-
Employees142
Founded2010
HeadquartersDallas, Texas, United States
SectorHealth Care
IndustryBiotechnology
Websitecgoncology.com
Analyst ratings
Based on 8 analysts giving stock ratings to CGON in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for CGON in the last 3 months.
Highest
Current $74.40
$102.00 (+37.10%)
Average
$90.00 (+20.97%)
Lowest
$80.00 (+7.53%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sean Laaman
Morgan Stanley
Buy
Reiterated
$102.00
+37.1%
11/13/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$84.00
+12.9%
11/09/2026
Bradley Canino
Guggenheim
Buy
Maintained
$89.00
+19.6%
11/09/2026
Boris Peaker
JonesTrading
Buy
Maintained
$85.00
+14.2%
11/06/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Maintained
$100.00
+34.4%
11/06/2026
Leonid Timashev
RBC Capital
Buy
Maintained
$80.00
+7.5%
11/06/2026
Unknown Analyst
Guggenheim
Buy
Initiated
$90.00
+21%
10/21/2026
Gregory Renza
Truist Financial
Buy
Maintained
-
-
09/10/2026
David Dai
UBS
Buy
Reiterated
$90.00
+21%
08/21/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$108.00
+45.2%
08/07/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Reiterated
$105.00
+41.1%
08/06/2026
Kelsey Goodwin
Piper Sandler
Buy
Reiterated
$85.00
+14.2%
08/07/2026
Alec Stranahan
Bank of America Securities
Buy
Reiterated
$88.00
+18.3%
08/07/2026
Kalpit Patel
Wolfe Research
Hold
Maintained
-
-
05/26/2026
Brian Cheng
J.P. Morgan
Buy
Reiterated
$96.00
+29%
05/11/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/11/2026
Soumit Roy
JonesTrading
Buy
Maintained
$85.00
+14.2%
04/06/2026
Last report
Nov 6, 2026
Fiscal period
Q3 2026
-$0.64 / -$0.81
+20.95%beat
Revenue / Est. (USD)
1.60M / 534.48K
+200.10%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
2.32M
1.08M
1.16M
1.60M
Cost of goods sold
33.03M
46.69M
58.58M
41.89M
Cost of revenue
33.03M
46.69M
58.58M
41.89M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
17.99M
20.78M
28.98M
22.96M
Operating expense
17.99M
20.78M
28.98M
22.96M
Total operating expenses
51.02M
67.47M
87.56M
64.85M
Operating income
-48.70M
-66.39M
-86.40M
-63.25M
Other non operating income
-53.00K
-101.00K
16.00K
-65.00K
EBT including unusual items
-41.31M
-60.20M
-79.06M
-56.89M
EBT excluding unusual items
-41.31M
-60.20M
-79.06M
-56.89M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-41.31M
-60.20M
-79.06M
-56.89M
Net profit margin
-1,779.03%
-5,558.82%
-6,832.84%
-3,546.82%
Earnings per share
-0.51
-0.71
-0.90
-0.64
Interest and investment income
7.44M
6.29M
7.33M
6.42M
Interest expense
-
-
-
-
Net interest expenses
7.44M
6.29M
7.33M
6.42M
Depreciation and amortization charges
-
-
-
-
EBITDA
-47.85M
-65.55M
-85.55M
-62.09M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps